Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for pa… Read more
Humanwell Healthcare Group Co Ltd (600079) - Net Assets
Latest net assets as of June 2025: CN¥21.41 Billion CNY
Based on the latest financial reports, Humanwell Healthcare Group Co Ltd (600079) has net assets worth CN¥21.41 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥37.56 Billion) and total liabilities (CN¥16.15 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥21.41 Billion |
| % of Total Assets | 57.0% |
| Annual Growth Rate | 18.89% |
| 5-Year Change | 59.95% |
| 10-Year Change | 125.37% |
| Growth Volatility | 22.69 |
Humanwell Healthcare Group Co Ltd - Net Assets Trend (2000–2024)
This chart illustrates how Humanwell Healthcare Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Humanwell Healthcare Group Co Ltd (2000–2024)
The table below shows the annual net assets of Humanwell Healthcare Group Co Ltd from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥20.69 Billion | +2.96% |
| 2023-12-31 | CN¥20.10 Billion | +12.02% |
| 2022-12-31 | CN¥17.94 Billion | +14.65% |
| 2021-12-31 | CN¥15.65 Billion | +20.97% |
| 2020-12-31 | CN¥12.94 Billion | -7.57% |
| 2019-12-31 | CN¥14.00 Billion | -1.93% |
| 2018-12-31 | CN¥14.27 Billion | -14.06% |
| 2017-12-31 | CN¥16.61 Billion | +38.59% |
| 2016-12-31 | CN¥11.98 Billion | +30.50% |
| 2015-12-31 | CN¥9.18 Billion | +60.31% |
| 2014-12-31 | CN¥5.73 Billion | +12.74% |
| 2013-12-31 | CN¥5.08 Billion | +39.20% |
| 2012-12-31 | CN¥3.65 Billion | +16.27% |
| 2011-12-31 | CN¥3.14 Billion | +34.86% |
| 2010-12-31 | CN¥2.33 Billion | +11.86% |
| 2009-12-31 | CN¥2.08 Billion | +67.79% |
| 2008-12-31 | CN¥1.24 Billion | +6.25% |
| 2007-12-31 | CN¥1.17 Billion | +5.24% |
| 2006-12-31 | CN¥1.11 Billion | +44.23% |
| 2005-12-31 | CN¥768.89 Million | +6.12% |
| 2004-12-31 | CN¥724.52 Million | +6.31% |
| 2003-12-31 | CN¥681.54 Million | -0.17% |
| 2002-12-31 | CN¥682.71 Million | +72.17% |
| 2001-12-31 | CN¥396.54 Million | +21.98% |
| 2000-12-31 | CN¥325.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Humanwell Healthcare Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 61422.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥9.59 Billion | 54.41% |
| Other Components | CN¥8.04 Billion | 45.59% |
| Total Equity | CN¥17.62 Billion | 100.00% |
Humanwell Healthcare Group Co Ltd Competitors by Market Cap
The table below lists competitors of Humanwell Healthcare Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brady Corporation
NYSE:BRC
|
$3.66 Billion |
|
Kobe Bussan Co. Ltd.
PINK:KOBNF
|
$3.66 Billion |
|
Haci Omer Sabanci Holding AS
IS:SAHOL
|
$3.66 Billion |
|
LegoChem Biosciences Inc
KQ:141080
|
$3.67 Billion |
|
iSoftStone Information Technology (Group) Co. Ltd.
SHE:301236
|
$3.65 Billion |
|
CLICKS GROUP LTD RC-01
F:N1C
|
$3.65 Billion |
|
WPG Holdings Ltd
TW:3702
|
$3.65 Billion |
|
Veren Inc
NYSE:VRN
|
$3.65 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Humanwell Healthcare Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,043,599,963 to 17,623,818,879, a change of 580,218,916 (3.4%).
- Net income of 1,329,744,984 contributed positively to equity growth.
- Dividend payments of 1,269,309,041 reduced retained earnings.
- Other factors increased equity by 519,782,972.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.33 Billion | +7.55% |
| Dividends Paid | CN¥1.27 Billion | -7.2% |
| Other Changes | CN¥519.78 Million | +2.95% |
| Total Change | CN¥- | 3.40% |
Book Value vs Market Value Analysis
This analysis compares Humanwell Healthcare Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.91x to 1.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥9.99 | CN¥19.11 | x |
| 2018-12-31 | CN¥8.01 | CN¥19.11 | x |
| 2019-12-31 | CN¥7.50 | CN¥19.11 | x |
| 2020-12-31 | CN¥6.97 | CN¥19.11 | x |
| 2021-12-31 | CN¥8.05 | CN¥19.11 | x |
| 2022-12-31 | CN¥9.21 | CN¥19.11 | x |
| 2023-12-31 | CN¥10.44 | CN¥19.11 | x |
| 2024-12-31 | CN¥10.80 | CN¥19.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Humanwell Healthcare Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.55%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.23%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 2.07x
- Recent ROE (7.55%) is below the historical average (8.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 12.66% | 19.30% | 0.36x | 1.80x | CN¥7.65 Million |
| 2001 | 9.75% | 11.95% | 0.24x | 3.34x | CN¥-740.50K |
| 2002 | 4.03% | 3.45% | 0.39x | 2.99x | CN¥-28.52 Million |
| 2003 | 6.02% | 5.37% | 0.34x | 3.31x | CN¥-20.31 Million |
| 2004 | 7.43% | 6.79% | 0.32x | 3.37x | CN¥-13.89 Million |
| 2005 | 8.85% | 6.88% | 0.37x | 3.52x | CN¥-6.68 Million |
| 2006 | 12.15% | 14.32% | 0.33x | 2.60x | CN¥19.05 Million |
| 2007 | 7.42% | 9.79% | 0.29x | 2.58x | CN¥-24.12 Million |
| 2008 | 7.77% | 7.63% | 0.40x | 2.54x | CN¥-22.41 Million |
| 2009 | 11.47% | 15.15% | 0.40x | 1.88x | CN¥25.87 Million |
| 2010 | 11.09% | 9.82% | 0.52x | 2.17x | CN¥21.23 Million |
| 2011 | 11.33% | 8.29% | 0.59x | 2.33x | CN¥35.30 Million |
| 2012 | 13.43% | 7.64% | 0.68x | 2.60x | CN¥103.76 Million |
| 2013 | 9.62% | 6.95% | 0.62x | 2.24x | CN¥-16.44 Million |
| 2014 | 9.57% | 6.45% | 0.58x | 2.58x | CN¥-20.51 Million |
| 2015 | 8.30% | 6.50% | 0.55x | 2.30x | CN¥-134.26 Million |
| 2016 | 8.29% | 6.75% | 0.47x | 2.63x | CN¥-171.72 Million |
| 2017 | 15.30% | 13.39% | 0.44x | 2.62x | CN¥716.33 Million |
| 2018 | -21.76% | -12.65% | 0.53x | 3.27x | CN¥-3.44 Billion |
| 2019 | 8.30% | 3.86% | 0.62x | 3.45x | CN¥-172.64 Million |
| 2020 | 10.67% | 5.64% | 0.64x | 2.94x | CN¥72.09 Million |
| 2021 | 10.57% | 6.80% | 0.59x | 2.62x | CN¥74.85 Million |
| 2022 | 16.52% | 11.12% | 0.62x | 2.40x | CN¥980.41 Million |
| 2023 | 12.52% | 8.70% | 0.68x | 2.12x | CN¥430.12 Million |
| 2024 | 7.55% | 5.23% | 0.70x | 2.07x | CN¥-432.64 Million |
Industry Comparison
This section compares Humanwell Healthcare Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Humanwell Healthcare Group Co Ltd (600079) | CN¥21.41 Billion | 12.66% | 0.75x | $3.66 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |